Tenet Healthcare (THC) Stock Forecast & Price Target

Tenet Healthcare is well positioned by a stronger competitive mix, improving cost structure, and an increasingly valuable USPI segment that is benefiting from high-acuity case migration, with 3Q USPI adjusted EBITDA of $537 million and 9% year-over-year growth. Its core business momentum appears resilient despite payer mix pressure, as uncompensated care stabilized from 2Q, hospital adjusted admissions rose 3.2%, and management is seeing 3-5% commercial pricing renewals with over 90% contracted for 2027. The outlook is further supported by roughly $5.13 billion of 2026 adjusted EBITDA, improving financial flexibility, and portfolio actions that should enhance returns through outpatient expansion, de novo development, and divestiture-driven capital allocation.

Tenet Healthcare is exposed to significant reimbursement and policy risk because a large portion of its business depends on Medicare and Medicaid, making earnings vulnerable to changes in government-sponsored payment rates and regulation. Its heavy concentration in several states also heightens geographic risk, especially given natural-disaster exposure in Arizona, California, Florida, and Texas, while shifts in payer mix can create volatile operating trends. A leveraged balance sheet and M&A-related execution risk at USPI further weaken the outlook, since management must successfully identify and integrate attractive surgery center targets to support growth.